Press releases

First-of-its-kind, rotation-free single-shot PFA catheter supported by strong safety and efficacy data adds to the groundbreaking Affera family of technologies in Europe Successful completion of...

One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib...

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety...

APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy Successful launch in Japan follows recent reimbursement approval Approvals across...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17,...

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April...

Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare...

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023

ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and...

SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ --...

Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias

Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN, March 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global...

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced that it received approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational...